Lu Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lu Lu has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Dun Niu
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications - Jianglang Ran
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications - Jiqin Lian
Department of Clinical Biochemistry, Army Medical University (Third Military Medical University), Chongqing, China
7 shared publications - Junshi Zhu
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications - Meihua Shan
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications - Mingzhen Yang
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications
Latest Publications
- Open Access
- 17 May 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38
Molecularly self-assembled nanoplatforms for targeted ROS-scavenging and neuroinflammation alleviation in acute ischemic stroke
- 17 May 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38
Open AccessMolecularly self-assembled nanoplatforms for targeted ROS-scavenging and neuroinflammation alleviation in acute ischemic stroke
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Comparison of the CDUPRT distribution, anti-tumor capacity and toxicity of mCDUPRT versus circCDUPRT after intravenous or intratumoral administration.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Comparison of the CDUPRT distribution, anti-tumor capacity and toxicity of mCDUPRT versus circCDUPRT after intravenous or intratumoral administration.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
The chemical structure of the 5-Flucytosine (5-FC), 5-Fluorouraci (5-FU) and 5-Fluoro-deoxyuridine monophosphate (5-FUMP).
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
The chemical structure of the 5-Flucytosine (5-FC), 5-Fluorouraci (5-FU) and 5-Fluoro-deoxyuridine monophosphate (5-FUMP).
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
The sequences of circGFP, circCDUPRT, circIL, and circScram
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
The sequences of circGFP, circCDUPRT, circIL, and circScram
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Comparison of mCDUPRT and circCDUPRT in vitro anti-tumor ability, protein translation ability and prodrug transformation ability under different concentrations and times.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Comparison of mCDUPRT and circCDUPRT in vitro anti-tumor ability, protein translation ability and prodrug transformation ability under different concentrations and times.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity. However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production. We developed an in vitro synthesized circRNA encoding the cytosine deaminase–uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models. In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15–expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity. However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production. We developed an in vitro synthesized circRNA encoding the cytosine deaminase–uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models. In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15–expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Validation of the tumor-targeting capacity and low toxicity of circCDUPRT on a 4T1 tumor-bearing mouse model.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Validation of the tumor-targeting capacity and low toxicity of circCDUPRT on a 4T1 tumor-bearing mouse model.
- 30 September 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (2) , 272-282
Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity. However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production. We developed an in vitro synthesized circRNA encoding the cytosine deaminase–uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models. In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15–expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.
- 30 September 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (2) , 272-282
Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity. However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production. We developed an in vitro synthesized circRNA encoding the cytosine deaminase–uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models. In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15–expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.
- 22 May 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (11) , 9953-9971
Enhanced Immunogenic Cell Death and Antigen Presentation via Engineered Bifidobacterium bifidum to Boost Chemo-immunotherapy
The immunogenic cell death (ICD) of tumor cells has aroused great interest in the field of immunotherapy, mainly due to the production of plentiful tumor-associated antigens (TAAs) and damage-associated molecule patterns. However, doxorubicin (DOX)-induced tumor-specific T-cell-mediated immune response is usually very weak because of antigen presentation deficiency and the immunosuppressive tumor microenvironment (ITME). Herein, the probiotic Bifidobacterium bifidum (Bi) was covalently modified with DOX-loaded CaP/SiO2 nanoparticles (DNPs@Bi) for tumor therapy. On one hand, the pH-responsive release of DOX could induce chemotherapy and ICD in the ITME. On the other hand, tumor-targeting Bi is able to significantly enhance the presentation of TAAs from B16F10 cells to DCs via Cx43-dependent gap junctions. Due to the combination of enhanced ICD and TAAs presentation, the maturation of DCs and the infiltration of cytotoxic T lymphocytes in the ITME were stimulated. As a result, in vivo antitumor experiments demonstrated that DNPs@Bi prolonged the survival rate and significantly inhibited the tumor progression and metastasis. This strategy of bacterial-driven hypoxia-targeting delivery systems offers a promising approach to tumor chemo-immunotherapy.
- 22 May 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (11) , 9953-9971
Enhanced Immunogenic Cell Death and Antigen Presentation via Engineered Bifidobacterium bifidum to Boost Chemo-immunotherapy
The immunogenic cell death (ICD) of tumor cells has aroused great interest in the field of immunotherapy, mainly due to the production of plentiful tumor-associated antigens (TAAs) and damage-associated molecule patterns. However, doxorubicin (DOX)-induced tumor-specific T-cell-mediated immune response is usually very weak because of antigen presentation deficiency and the immunosuppressive tumor microenvironment (ITME). Herein, the probiotic Bifidobacterium bifidum (Bi) was covalently modified with DOX-loaded CaP/SiO2 nanoparticles (DNPs@Bi) for tumor therapy. On one hand, the pH-responsive release of DOX could induce chemotherapy and ICD in the ITME. On the other hand, tumor-targeting Bi is able to significantly enhance the presentation of TAAs from B16F10 cells to DCs via Cx43-dependent gap junctions. Due to the combination of enhanced ICD and TAAs presentation, the maturation of DCs and the infiltration of cytotoxic T lymphocytes in the ITME were stimulated. As a result, in vivo antitumor experiments demonstrated that DNPs@Bi prolonged the survival rate and significantly inhibited the tumor progression and metastasis. This strategy of bacterial-driven hypoxia-targeting delivery systems offers a promising approach to tumor chemo-immunotherapy.
- Top Cited Papers
- 18 January 2022
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (2) , 2381-2398
Multienzyme-like Reactivity Cooperatively Impairs Glutathione Peroxidase 4 and Ferroptosis Suppressor Protein 1 Pathways in Triple-Negative Breast Cancer for Sensitized Ferroptosis Therapy
Ferroptosis is a recently discovered route of regulated cell death that offers the opportunities for the treatment of chemotherapy-resistant tumor indications, but its efficacy can be affected by the glutathione peroxidase 4 (GPX4) and ferroptosis suppressor protein 1 (FSP1) antioxidant mechanisms, posing significant challenges for its clinical translation. In this study, we report a Cu-tetra(4-carboxyphenyl)porphyrin chloride(Fe(III)) (Cu-TCPP(Fe)) metal organic framework (MOF)-based nanosystem for the efficient incorporation of Au nanoparticles (NPs) and RSL3, which can demonstrate enzyme-like activities to universally suppress the antiferroptotic pathways in tumor cells for amplifying ferroptotic damage. Herein, Cu-TCPP(Fe) MOF nanosheets were integrated with Au NPs via in situ nucleation and loaded with RSL3 via π–π stacking, which were eventually modified with polyethylene glycol (PEG) and iRGD for tumor-targeted drug delivery. Specifically, the Au NPs can demonstrate glucose oxidase-like activities for efficient glucose depletion, thus disrupting the pentose phosphate pathway to impede reduced glutathione (GSH) biosynthesis and prevent the recycling of coenzyme Q10 (CoQ10) to CoQ10H2, while Cu species can oxidize GSH into oxidized glutathione (GSSG). These nanocatalytic activities can lead to the simultaneous inhibition of the GPX4/GSH and FSP1/CoQ10H2 pathways and cooperate with the GPX4-deactivating function of RSL3 to cause pronounced ferroptotic damage, thereby providing a strong rationale for the application of ferroptosis therapy in the clinic.
- 18 January 2022
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (2) , 2381-2398
Top Cited PapersMultienzyme-like Reactivity Cooperatively Impairs Glutathione Peroxidase 4 and Ferroptosis Suppressor Protein 1 Pathways in Triple-Negative Breast Cancer for Sensitized Ferroptosis Therapy
Ferroptosis is a recently discovered route of regulated cell death that offers the opportunities for the treatment of chemotherapy-resistant tumor indications, but its efficacy can be affected by the glutathione peroxidase 4 (GPX4) and ferroptosis suppressor protein 1 (FSP1) antioxidant mechanisms, posing significant challenges for its clinical translation. In this study, we report a Cu-tetra(4-carboxyphenyl)porphyrin chloride(Fe(III)) (Cu-TCPP(Fe)) metal organic framework (MOF)-based nanosystem for the efficient incorporation of Au nanoparticles (NPs) and RSL3, which can demonstrate enzyme-like activities to universally suppress the antiferroptotic pathways in tumor cells for amplifying ferroptotic damage. Herein, Cu-TCPP(Fe) MOF nanosheets were integrated with Au NPs via in situ nucleation and loaded with RSL3 via π–π stacking, which were eventually modified with polyethylene glycol (PEG) and iRGD for tumor-targeted drug delivery. Specifically, the Au NPs can demonstrate glucose oxidase-like activities for efficient glucose depletion, thus disrupting the pentose phosphate pathway to impede reduced glutathione (GSH) biosynthesis and prevent the recycling of coenzyme Q10 (CoQ10) to CoQ10H2, while Cu species can oxidize GSH into oxidized glutathione (GSSG). These nanocatalytic activities can lead to the simultaneous inhibition of the GPX4/GSH and FSP1/CoQ10H2 pathways and cooperate with the GPX4-deactivating function of RSL3 to cause pronounced ferroptotic damage, thereby providing a strong rationale for the application of ferroptosis therapy in the clinic.